

DAFTAR PUSTAKA

- Adsay,N.V., Al-Ahmadi,H., Appelman,H.D., Argani,P., Atkins,K.A., Baloch,Z.,W., Balos,L.L., Barreto,J.E., Basturk,O., Beckwith, J.B., Berney,D.M. (2015). *Sternberg's diagnostic surgical pathology*. Sixth Edition. Philadelphia: Wolters Kluwer Health. Hal. 752-791.
- Ali, N. S. H. dan Mohammed, Z. I. (2019) ‘Gene expression of tumor suppresser protein (p53 gene) and histopathological study of tonsillitis tissue’, (April). Diakses pada tanggal 11 November 2019.
- A.S.Y. Leong. (2011). A pattern approach to lymph node diagnosis. Hal. 194. Springer Science+Business Media, LLC. Diakses pada tanggal 1 Juli 2020.
- Banham, H.A., Beasley N., Camp, E., Fernandez, L.P., Fidler C., Gatter K., Jones , M. Mason Y.D., Prime E.J., Philippe,T., Wood,K., and Cordell,L.J. (2001) ‘The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p’, *Cancer Research*, 61(24), pp. 8820–8829. Diakses pada tanggal 31 Oktober 2019.
- Banham, A. H., Connors, J. M., Brown, P.J., Cordell, J.L., Ott,G., Sreenivasan, G., Farinha, P.Horsman, D.E.,Gascoyne, R.D. (2005) ‘Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma’, *Clinical Cancer Research*, 11(3), pp. 1065–1072. Diakses pada tanggal 31 Oktober 2019.
- Cerna, K., Oppelt, J., Chocola, V., Musilova, K., Seda, V., Pavsalova, G., Radova, L., Arigoni, M., Calogero, R.A., Benes, V., Trbusek, M., Brychtova, Y., Doubek, M., Mayer, J., Pospisilova, S., Mraz, M., (2019) “MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells,” *Leukemia*. Springer US, 33(2), hal. 403–414. Diakses pada tanggal 14 September 2019.
- Cerna, K. dan Mraz, M. (2018) “P53 limits B cell receptor (BCR) signalling: A new role for miR-34a and FOXP1,” *Oncotarget*, 9(92), hal. 36409–36410. Diakses pada tanggal 17 September 2019.
- Dojcinov, S., Wilkins, B. dan Calaminici, M. (2015) ‘Standards for specialist laboratory integration and dataset for the histopathological reporting of lymphomas October 2015’, (October). 2 November 2019.
- Donizy, P., Pagacz,K., Marczuk, J., Fendler, W., Maciejzyk, A., Halon, A., dan Matkowski,R.. (2018) ‘Upregulation of FOXp1 is a new independent unfavorable prognosticator and a specific predictor of lymphatic dissemination in cutaneous melanoma patients’, *Oncotargets and Therapy*, 11, pp. 1413–1422. Diakses pada tanggal 18 Oktober 2019.

- Ehsan, A. Fan,H., Eagan, P.A., Siddiqui,H.A., dan Gulley,M.L.. (2000) ‘Accumulation of p53 in infectious mononucleosis tissues’, *Human Pathology*, 31(11), pp. 1397–1403. Diakses pada tanggal 1 November 2019.
- Excellence, C. (2016) Non-Hodgkin ’ s lymphoma : diagnosis and management NICE guideline: methods , evidence and recommendations. Diakses pada tanggal 29 Juli 2020
- Goldstein, I., Marcel, V., Olivier, M., Oren, M., Rotter, V., dan Hainaut, P. (2011) “Understanding wild-type and mutant p53 activities in human cancer: New landmarks on the way to targeted therapies,” *Cancer Gene Therapy*. Nature Publishing Group, 18(1), hal. 2–11. Diakses pada tanggal 6 Juli 2020.
- Halacli, S. O. dan Dogan, A. L. (2015) ‘FOXP1 regulation via the PI3K/Akt/p70S6K signaling pathway in breast cancer cells’, *Oncology Letters*, 9(3), pp. 1482–1488. Diakses pada tanggal 22 Oktober 2019.
- Hans, C. P., Weisenburger D.D., Greiner, T.C., Gascoyne,R.D. , Delabie, J., Ott, G., Müller-Hermelink, H.K., Campo, E., Braziel, R.M., Jaffe, E.S., Pan, Z., Farinha, P., Smith L M., Falini, B, Banham, A. H., Rosenwald, A, Staudt, L.M., Connors,J.M., Armitage, J.O. and Chan,W.C. (2004) ‘Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray’, *Blood*, 103(1), pp. 275–282. Diakses pada tanggal 31 Oktober 2019.
- He, M., Gao, L, Zhang, S., Tao, L., Wang, J., Yang, J., dan Zhu, M. (2014).“Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL,” *Gastric Cancer*, 17(3), hal. 431–441. Diakses pada tanggal 30 September 2019.
- Ioachim,H.L., Medeiros, L.J.(2009). Ioachim’s Lymph Node Pathology. Fourth Edition. Philadelphia: Lippincot Williams & Wilkins. Hal. 172-185
- Jethwa, A. Słabicki, M., Hullein, J., Jentzsch, M., Dalal, V., Rabe, S., Wagner, L, Walther, T., Klapper, W., Bohnenberger, H., Rettel, M., Lu, J., Smits, A.H., Stein, F., Savitski, M.M., Huber, W., Aylon, Y., Oren, M., Zenz, T. (2018) “TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma,” *Blood*, 131(25), hal. 2789–2802. Diakses pada tanggal 7 Juli 2020.
- Kanavaros, P. et al. (2000) “Expression of p53, p21 /waf1 , bcl-2, bax,Rb and Ki67 proteins in Hodgkin ’ s lymphomas,” *Histology and Histopathology*.hal. 445–453.
- Kim, E., Giese, A. dan Deppert, W. (2009) “Wild-type p53 in cancer cells: When a guardian turns into a blackguard,” *Biochemical Pharmacology*, 77(1), hal.

11–20. doi: 10.1016/j.bcp.2008.08.030. Diakses pada tanggal 6 Juli 2020.

Kondratovskii, P. M., Dubikov, A. I., Doroshevskaya, A. Yu., and Eliseikina, M. G.. (2014) ‘PUMA protein in p53 regulatory molecule pattern determines the prognosis for patients with lymphoproliferative diseases’, *Bulletin of Experimental Biology and Medicine*, 156(6), pp. 849–853. Diakses pada tanggal 31 Oktober 2019.

Koon, H. B., Ippolito, G. C, Banham A H. dan Tucker, P.W. (2007) ‘FOXP1 : a potential therapeutic target in cancer’, (August). Diakses pada tanggal 28 Oktober 2019.

Kumar, V., Abbas, A.K., and Aster, J.C. (2015). Robbins and cotran pathologic basic of disease. Ninth Edition. Philadelphia: Elsevier. Hal. 606-607.

Martin Köbel1, W. G. M., C Blake Gilks dan Naveena Singh (2016) “Interpretation of p53 immunohistochemistry in tubo-ovarian carcinoma: guidelines for reporting,” *The British Association of Gynaecological Pathologists*, (October), hal. 1–17. doi: 10.1007/978-3-662-56333-5_4. Diakses pada tanggal 27 Juli 2020.

Montgomery, N. D. dan Fedoriw, Y. (2014) “Pathology consultation on intermediate-to-large B-Cell lymphomas,” *American Journal of Clinical Pathology*, 141(3), hal. 305–317. Diakses pada tanggal 11 Juli 2020.

Patzelt, T. Keppler, S.J., Gorka, S., Thoene, S., Wartewig, T., Reth, M., Förster, I., Lang, R., Buchner, M., dan Ruland, J. (2018) “Foxp1 controls mature B cell survival and the development of follicular and B-1 B cells,” hal. 1–6. Diakses pada tanggal 4 Juli 2020.

Qin, L. X., Tang, Z.Y., Ma, Z.C., Wu, Z.Q., Zhou, X.D., Ye, Q.H., Ji, Y., Huang, L.W., Jia, H.L., Sun, H.C., and Wang, L. (2002) ‘P53 immunohistochemical scoring: An independent prognostic marker for patients after hepatocellular carcinoma resection’, *World Journal of Gastroenterology*, 8(3), pp. 459–463. Diakses pada tanggal 21 Oktober 2019.

Rao, D. S., O'Connell, R.M., Chaudhuri, A.A., Flores, Y.G., Geiger, T.L., and Baltimore, D. (2010) ‘Article MicroRNA-34a perturbs b lymphocyte development by repressing the forkhead box transcription factor FOXP1’, *Immunity*. Elsevier Ltd, 33(1), pp. 48–59. Diakses pada tanggal 10 November 2019.

Rosai, J. (2011). Rosai and Ackerman’s surgical pathology. Tenth Edition. London: Elsevier Inc. page 1771-1780.

Rosner, B. (2016). Fundamental of biostatistics. Chicago: Cengage Learning. page 300-315.

Rouhigharabaei, L., Ferreiro,J.F., Tousseyn,T., van der Krog,J., Put,N.. Haralambieva, and Graux,C.E. (2014) ‘Non-IG aberrations of FOXP1 in B-cell malignancies lead to an aberrant expression of N-truncated isoforms of FOXP1’, *PLoS ONE*, 9(1). Diakses pada tanggal 15 Oktober 2019.

Singh, N., Piskorz, A.M., Bosse, T., Linan, M.J., Rous, B., Brenton, J.D., Gilks, C.B., Köbel, M. (2020) “p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies,” *Journal of Pathology*, 250(3), hal. 336–345. doi: 10.1002/path.5375. Diakses pada tanggal 23 Juli 2020.

Slack, G. W. (2016) “The pathology of reactive lymphadenopathies: A discussion of common reactive patterns and their malignant mimics,” *Archives of Pathology and Laboratory Medicine*, 140(9), hal. 881–892. doi: 10.5858/arpa.2015-0482-SA. Diakses pada tanggal 23 Juli 2020.

Stefancikova, L., Moulis, M., Fabian, P., Ravcukova, B., Vasova, I., Muzik, J., Malcikova J., Falkova, I., Slovackova, J., and Smardova, J.(2010). Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma in mantle cell lymphoma. *International journal of oncology*. 36: 699-706. Diakses pada tanggal 1 Oktober 2019.

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, and Thiele J. (2017). *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue*. (Revised 4th edition). IARC: Lyon.

Van Keimpema, M.. Gruneberg, L.J., Mokry,M., van Boxtel, R., Koster,J., Coffer,P.J. Pals, S.T., and Spaargaren, M. (2014) ‘FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cells’, *Blood*, 124(23), pp. 3431–3440. Diakses pada tanggal 19 Oktober 2019.

Van Krieken, J. H. J. M. Langerak, A.W., Macintyre,E.A., Kneba, M., Hodges, E., Sanz R. G., Morgan, G.J., Parreira, A., Molina, T.J., Cabecadas,J.and Gaulard,P. (2007) ‘Improved reliability of lymphoma diagnostics via PCR-based clonality testing: - Report of the BIOMED-2 Concerted Action BHMA4-CT98-3936’, *Leukemia*, 21(2), pp. 201–206. Diakses pada tanggal 19 Oktober 2019.

Voropaeva, E. N., Pospelova, T.I., Voevoda, M.i., Maksimov, V.N., Orlov, Y.L., dan Seregina, O.B. (2019) “Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma,” 12(Suppl 2), hal. 35–44. Diakses pada tanggal 7 Juli 2020.

Wang, X. J. Medeiros L. J., Bueso-Ramos, C. E., Tang,G., Wang, S., Oki, Y., Desai, P., Khouri, J.D., Miranda,R.N., Tang,Z. Reddy,N., and Li,S. (2017) ‘P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent

MYC/BCL2 expression in diffuse large B-cell lymphoma', *Modern Pathology*. Nature Publishing Group, 30(2), pp. 194–203. Diakses pada tanggal 7 November 2019.

Xie, Y., Bulbul, M.A., Ji, L., Inouye, C.M., Groshen, S.G., Tupule,A. O'Malley,D.P., Wang, E., and Siddiqi, I.N. (2014) 'P53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: A Single Institutional Clinicopathologic Study', *American Journal of Clinical Pathology*, 141(4), pp. 593–604. Diakses pada tanggal 7 November 2019.

Xu-monette, Z. Y., Medeiros, L.J., Li, Y., Orlowski, R.Z., Andreeff, M., Bueso-Ramos, C.E., Greiner, T.C., McDonnell, T.J., and Young, K.H. (2012) 'Malignancies dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies', pp. 3668–3683. Diakses pada tanggal 9 November 2019.

Yu, B. H. Zhou, X.Y., Li, B.Z., Xiao, X.Y., Yan, S.Y.,and Shi, D.R. (2011) 'FOXP1 expression and its clinicopathologic significance in nodal and extranodal diffuse large B-cell lymphoma', *Annals of Hematology*, 90(6), pp. 701–708. Diakses pada tanggal 15 September 2019.

Yu, G., Wang, H., Hu, Z., Zhang, S., Qi, Y., Liu, J., Zhu, L., and Lin,B. (2017). 'Correlation between FOXP1 and ER/PR expression in endometrial carcinoma', *OncoTarget*, pp. 1–13. Diakses pada tanggal 22 Oktober 2019.